Latest article
Lilly’s tirzepatide beats Ozempic in head-to-head kind 2 diabetes trial
Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Coronavirus pandemic fueled new health tendencies, analysis exhibits – WISH-TV | Indianapolis Information |...
INDIANAPOLIS (WISH) — The...
Diabetes-focused healthcare startup Breathe Properly-being raises $ 1 million in pre-series A spherical led...
Thanks to the pandemic, many companies have seen significant financial growth this year, thanks in particular to the unprecedented surge in business opportunities...